Are there any new medications for glaucoma in development?

300 micrograms/mL preservative-free eye drops (Lumigan ® single-dose eye drops) for reduction of elevated intraocular pressure in chronic open-angle glaucoma ... Aug 5, 2024 ... The funded brand of Bimatoprost 0.03% eye drops is changing from Bimatoprost (Multichem) to Lumigan. This change began on 1 August 2024. How is bimatoprost used? One drop of bimatoprost should be applied directly to the base of the upper eyelashes, once a day at night. Each application of ... Latisse (bimatoprost ophthalmic solution) is the first and only prescription treatment approved by the FDA for inadequate eyelashes, growing them longer ... Bimatoprost has been used for many years for treating glaucoma. (abnormal eye pressures) prior to the arrival of Latisse to the market to treat eyelash growth. Apr 22, 2025 ... ... bimatoprost in a non ... 24-month phase I/II clinical trial of bimatoprost sustained-release implant (bimatoprost SR) in glaucoma patients. DURYSTA® (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular ... Bimatoprost ... Bimatoprost is a monocarboxylic acid amide. It has a role as an antiglaucoma drug and an antihypertensive agent. ChEBI. Bimatoprost, also known as ... Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. ... Specifically it is ... DURYSTA (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular ...